Ethyl biscoumacetate

Identification

Name
Ethyl biscoumacetate
Accession Number
DB08794
Type
Small Molecule
Groups
Withdrawn
Description

Ethyl biscoumacetate is a courmarin that is used as an anticoagulant. It has actions similar to those of Warfarin. (From Martindale, The Extra Pharmacopoeia, 30th ed, p226)

Structure
Thumb
Synonyms
  • Ethyl bis(4-hydroxy-2-oxo-2h-1-benzopyran-3-yl)acetate
  • Ethyldicoumarol
International/Other Brands
Pelentan / Tromexan
Categories
UNII
08KL644731
CAS number
548-00-5
Weight
Average: 408.362
Monoisotopic: 408.084517475
Chemical Formula
C22H16O8
InChI Key
JCLHQFUTFHUXNN-UHFFFAOYSA-N
InChI
InChI=1S/C22H16O8/c1-2-28-20(25)15(16-18(23)11-7-3-5-9-13(11)29-21(16)26)17-19(24)12-8-4-6-10-14(12)30-22(17)27/h3-10,15,23-24H,2H2,1H3
IUPAC Name
ethyl 2,2-bis(4-hydroxy-2-oxo-2H-chromen-3-yl)acetate
SMILES
CCOC(=O)C(C1=C(O)C2=CC=CC=C2OC1=O)C1=C(O)C2=CC=CC=C2OC1=O

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limonene(4R)-limonene may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
AbciximabAbciximab may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
AceclofenacAceclofenac may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
AcemetacinThe risk or severity of bleeding can be increased when Ethyl biscoumacetate is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolAcenocoumarol may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
AcetaminophenAcetaminophen may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
AcetohexamideAcetohexamide may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational, Withdrawn
Acetylsalicylic acidAcetylsalicylic acid may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved
AdapaleneAdapalene may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
AlaproclateAlaproclate may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
AlclofenacAlclofenac may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Withdrawn
AllopurinolAllopurinol may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
AllylestrenolThe therapeutic efficacy of Ethyl biscoumacetate can be decreased when used in combination with Allylestrenol.Approved
AlminoprofenAlminoprofen may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
AloxiprinAloxiprin may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
AlprostadilAlprostadil may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
AlteplaseAlteplase may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
AltrenogestThe therapeutic efficacy of Ethyl biscoumacetate can be decreased when used in combination with Altrenogest.Vet Approved
Aluminium clofibrateAluminium clofibrate may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
AmdinocillinAmdinocillin may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational, Withdrawn
AmineptineAmineptine may increase the anticoagulant activities of Ethyl biscoumacetate.Illicit, Withdrawn
Aminosalicylic AcidAminosalicylic Acid may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
AmiodaroneThe therapeutic efficacy of Ethyl biscoumacetate can be increased when used in combination with Amiodarone.Approved, Investigational
AmitriptylineAmitriptyline may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
AmitriptylinoxideAmitriptylinoxide may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
AmobarbitalThe metabolism of Ethyl biscoumacetate can be increased when combined with Amobarbital.Approved, Illicit
AmoxapineAmoxapine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
AmoxicillinAmoxicillin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved
AmpicillinAmpicillin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved
AnagrelideAnagrelide may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
AncrodAncrod may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
AndrographolideAndrographolide may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
AnisodamineAnisodamine may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
AnistreplaseAnistreplase may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
AntipyrineAntipyrine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
Antithrombin III humanEthyl biscoumacetate may increase the anticoagulant activities of Antithrombin III human.Approved
AntrafenineAntrafenine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
ApixabanApixaban may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
ApocyninApocynin may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
ApremilastApremilast may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
AprotininThe therapeutic efficacy of Ethyl biscoumacetate can be decreased when used in combination with Aprotinin.Approved, Investigational, Withdrawn
ArdeparinArdeparin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational, Withdrawn
ArgatrobanArgatroban may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
AspoxicillinAspoxicillin may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
AstaxanthinAstaxanthin may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
AzapropazoneAzapropazone may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
AzathioprineAzathioprine may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved
AzelastineAzelastine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Ethyl biscoumacetate is combined with Azficel-T.Approved, Investigational
AzidocillinAzidocillin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
AzithromycinThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Azithromycin.Approved
AzlocillinAzlocillin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
BacampicillinBacampicillin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
BalsalazideBalsalazide may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
BarbexacloneThe metabolism of Ethyl biscoumacetate can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Ethyl biscoumacetate can be increased when combined with Barbital.Illicit
BatroxobinBatroxobin may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
BazedoxifeneBazedoxifene may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
BecaplerminBecaplermin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
BemiparinBemiparin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
BendazacBendazac may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
BenorilateBenorilate may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
BenoxaprofenBenoxaprofen may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
BenzydamineBenzydamine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
BenzylpenicillinBenzylpenicillin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved
Benzylpenicilloyl PolylysineBenzylpenicilloyl Polylysine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
BeraprostBeraprost may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
BevoniumBevonium may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
BezafibrateBezafibrate may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
BicalutamideThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Bicalutamide.Approved
BivalirudinBivalirudin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
BosentanThe metabolism of Ethyl biscoumacetate can be increased when combined with Bosentan.Approved, Investigational
BrinaseBrinase may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
BromfenacBromfenac may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
BucillamineBucillamine may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
BufexamacBufexamac may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Experimental
BuflomedilBuflomedil may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
BumadizoneBumadizone may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
ButriptylineButriptyline may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
ButylphthalideButylphthalide may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
CangrelorCangrelor may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
CapecitabineThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Capecitabine.Approved, Investigational
CaplacizumabCaplacizumab may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
CapsaicinCapsaicin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
CarbamazepineThe serum concentration of Ethyl biscoumacetate can be decreased when it is combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumCarbaspirin calcium may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental, Investigational
CarbenicillinCarbenicillin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
Carbenicillin indanylCarbenicillin indanyl may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
CarbimazoleCarbimazole may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
CarbomycinThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Carbomycin.Vet Approved
CarbutamideCarbutamide may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
CarfecillinCarfecillin may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
CarprofenCarprofen may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
CefacetrileCefacetrile may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
CefaclorCefaclor may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
CefadroxilCefadroxil may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved, Withdrawn
CefalotinCefalotin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational, Vet Approved
CefamandoleCefamandole may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
CefapirinCefapirin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved
CefatrizineCefatrizine may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
CefazedoneCefazedone may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
CefazolinCefazolin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
CefbuperazoneCefbuperazone may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
CefcapeneCefcapene may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
CefdinirCefdinir may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
CefditorenCefditoren may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
CefepimeCefepime may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
CefetametCefetamet may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
CefiximeCefixime may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
CefmenoximeCefmenoxime may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
CefmetazoleCefmetazole may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
CefminoxCefminox may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
CefodizimeCefodizime may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
CefonicidCefonicid may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
CefoperazoneCefoperazone may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
CeforanideCeforanide may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
CefotaximeCefotaxime may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
CefotetanCefotetan may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
CefotiamCefotiam may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
CefoxitinCefoxitin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
CefozopranCefozopran may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
CefpiromeCefpirome may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
CefpodoximeCefpodoxime may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved
CefprozilCefprozil may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
CefradineCefradine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
CefroxadineCefroxadine may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
CefsulodinCefsulodin may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
Ceftaroline fosamilCeftaroline fosamil may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
CeftazidimeCeftazidime may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
CeftezoleCeftezole may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
CeftibutenCeftibuten may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
CeftizoximeCeftizoxime may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
CeftobiproleCeftobiprole may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
CeftriaxoneCeftriaxone may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
CefuroximeCefuroxime may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
CelecoxibCelecoxib may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
CephalexinCephalexin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational, Vet Approved
CephaloglycinCephaloglycin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
CephaloridineCephaloridine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Withdrawn
CertoparinEthyl biscoumacetate may increase the anticoagulant activities of Certoparin.Approved, Investigational
Chloral hydrateThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChloramphenicolChloramphenicol may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved
ChlormadinoneChlormadinone may decrease the anticoagulant activities of Ethyl biscoumacetate.Experimental
ChloroquineChloroquine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational, Vet Approved
ChlorotrianiseneChlorotrianisene may decrease the anticoagulant activities of Ethyl biscoumacetate.Investigational, Withdrawn
ChlorphenesinChlorphenesin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved, Withdrawn
ChlorpropamideChlorpropamide may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
ChlortetracyclineChlortetracycline may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational, Vet Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Ethyl biscoumacetate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateCholine magnesium trisalicylate may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
CilostazolCilostazol may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
CimetidineCimetidine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
CimicoxibCimicoxib may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
CinoxacinCinoxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational, Withdrawn
CiprofibrateCiprofibrate may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
CiprofloxacinThe therapeutic efficacy of Ethyl biscoumacetate can be increased when used in combination with Ciprofloxacin.Approved, Investigational
CisplatinCisplatin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
CitalopramCitalopram may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
ClarithromycinThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Clarithromycin.Approved
Clodronic AcidClodronic Acid may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational, Vet Approved
ClofibrateClofibrate may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
ClofibrideClofibride may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
ClomipramineClomipramine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational, Vet Approved
ClonixinClonixin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
ClopidogrelClopidogrel may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
CloricromenCloricromen may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
ClorindioneClorindione may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
ClotrimazoleThe metabolism of Ethyl biscoumacetate can be decreased when combined with Clotrimazole.Approved, Vet Approved
CloxacillinCloxacillin may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational, Vet Approved
ColesevelamColesevelam can cause a decrease in the absorption of Ethyl biscoumacetate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Ethyl biscoumacetate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Collagenase clostridium histolyticumThe risk or severity of adverse effects can be increased when Ethyl biscoumacetate is combined with Collagenase clostridium histolyticum.Approved, Investigational
Conjugated estrogensConjugated estrogens may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved
CranberryCranberry may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
CurcuminCurcumin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
CyclacillinCyclacillin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
CyclobenzaprineThe risk or severity of bleeding can be increased when Cyclobenzaprine is combined with Ethyl biscoumacetate.Approved
CyclosporineThe metabolism of Ethyl biscoumacetate can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateCyproterone acetate may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
Dabigatran etexilateDabigatran etexilate may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
DaidzeinDaidzein may decrease the anticoagulant activities of Ethyl biscoumacetate.Experimental
DalteparinDalteparin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
DanaparoidDanaparoid may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Withdrawn
DanazolDanazol may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
DapoxetineDapoxetine may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
DarexabanEthyl biscoumacetate may increase the anticoagulant activities of Darexaban.Investigational
DasatinibDasatinib may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
DeferasiroxThe risk or severity of adverse effects can be increased when Ethyl biscoumacetate is combined with Deferasirox.Approved, Investigational
DefibrotideDefibrotide may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
DemeclocyclineDemeclocycline may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
DemegestoneThe therapeutic efficacy of Ethyl biscoumacetate can be decreased when used in combination with Demegestone.Approved
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Ethyl biscoumacetate is combined with Deoxycholic Acid.Approved
DersalazineDersalazine may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
DesipramineDesipramine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
DesirudinEthyl biscoumacetate may increase the anticoagulant activities of Desirudin.Approved
DesmoteplaseDesmoteplase may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
DesogestrelDesogestrel may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Ethyl biscoumacetate.Approved, Investigational
DexamethasoneThe serum concentration of Ethyl biscoumacetate can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexibuprofenDexibuprofen may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
DexketoprofenDexketoprofen may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
DexmethylphenidateThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Dexmethylphenidate.Approved, Investigational
DextranEthyl biscoumacetate may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DibenzepinDibenzepin may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
DiclofenacDiclofenac may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved
DicloxacillinDicloxacillin may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational, Vet Approved
DicoumarolDicoumarol may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
DienestrolDienestrol may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
DienogestDienogest may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved
DiethylstilbestrolDiethylstilbestrol may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
DifenpiramideDifenpiramide may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
DiflunisalDiflunisal may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
DiltiazemThe metabolism of Ethyl biscoumacetate can be decreased when combined with Diltiazem.Approved, Investigational
DimetacrineDimetacrine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Withdrawn
DiphenadioneDiphenadione may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
DipyridamoleDipyridamole may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
DisulfiramThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Disulfiram.Approved
DitazoleDitazole may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Withdrawn
DosulepinDosulepin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
DoxepinDoxepin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
DoxycyclineDoxycycline may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational, Vet Approved
DronedaroneThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Dronedarone.Approved
DrospirenoneDrospirenone may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved
Drotrecogin alfaDrotrecogin alfa may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational, Withdrawn
DroxicamDroxicam may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
DuloxetineDuloxetine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
DuvelisibDuvelisib may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
DydrogesteroneThe therapeutic efficacy of Ethyl biscoumacetate can be decreased when used in combination with Dydrogesterone.Approved, Investigational, Withdrawn
E-6201E-6201 may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
EconazoleThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Econazole.Approved
Edetic AcidEdetic Acid may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved
EdoxabanEdoxaban may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
EfavirenzThe serum concentration of Ethyl biscoumacetate can be decreased when it is combined with Efavirenz.Approved, Investigational
EnoxacinEnoxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
EnoxaparinEnoxaparin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
EpicillinEpicillin may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
EpimestrolEpimestrol may decrease the anticoagulant activities of Ethyl biscoumacetate.Experimental
EpinastineEpinastine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
EpirizoleEpirizole may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
EplivanserinEplivanserin may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
EpoprostenolEpoprostenol may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
EptifibatideEptifibatide may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
EquolEquol may decrease the anticoagulant activities of Ethyl biscoumacetate.Investigational
ErythromycinThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Erythromycin.Approved, Investigational, Vet Approved
EscitalopramEscitalopram may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
EsomeprazoleThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Esomeprazole.Approved, Investigational
EstradiolEstradiol may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational, Vet Approved
Estradiol acetateEstradiol acetate may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational, Vet Approved
Estradiol cypionateEstradiol cypionate may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational, Vet Approved
Estradiol valerateEstradiol valerate may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational, Vet Approved
EstriolEstriol may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational, Vet Approved
Estrogens, esterifiedEstrogens, esterified may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved
EstroneEstrone may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved
Etacrynic acidThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Etacrynic acid.Approved, Investigational
EtanerceptEtanercept may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
EthanolThe serum concentration of Ethyl biscoumacetate can be decreased when it is combined with Ethanol.Approved
EthenzamideEthenzamide may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
Ethinyl EstradiolEthinyl Estradiol may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved
EthotoinEthotoin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
EthynodiolThe therapeutic efficacy of Ethyl biscoumacetate can be decreased when used in combination with Ethynodiol.Experimental
Ethynodiol diacetateEthynodiol diacetate may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved
EtodolacEtodolac may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
EtofibrateEtofibrate may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
EtonogestrelEtonogestrel may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
EtoperidoneEtoperidone may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtoposideEtoposide may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
EtoricoxibEtoricoxib may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
Evening primrose oilEvening primrose oil may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational, Nutraceutical
EverolimusThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Everolimus.Approved
ExenatideExenatide may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
ExisulindExisulind may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
FelbinacFelbinac may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
FenbufenFenbufen may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
FenofibrateFenofibrate may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
Fenofibric acidThe risk or severity of bleeding can be increased when Fenofibric acid is combined with Ethyl biscoumacetate.Approved
FenoprofenFenoprofen may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
FentiazacFentiazac may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
FeprazoneFeprazone may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
Ferulic acidFerulic acid may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
FibrinolysinFibrinolysin may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
FleroxacinFleroxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
FloctafenineFloctafenine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Withdrawn
FlucloxacillinFlucloxacillin may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
FluconazoleThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Fluconazole.Approved, Investigational
FluindioneEthyl biscoumacetate may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequineFlumequine may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
FlunixinFlunixin may increase the anticoagulant activities of Ethyl biscoumacetate.Vet Approved
FlunoxaprofenFlunoxaprofen may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
FluorouracilThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Fluorouracil.Approved
FluoxetineFluoxetine may increase the antiplatelet activities of Ethyl biscoumacetate.Approved, Vet Approved
FluoxymesteroneFluoxymesterone may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Illicit
FlurbiprofenFlurbiprofen may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
FluvastatinThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Fluvastatin.Approved
FluvoxamineFluvoxamine may increase the antiplatelet activities of Ethyl biscoumacetate.Approved, Investigational
FondaparinuxFondaparinux sodium may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
FosphenytoinFosphenytoin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
FurosemideThe therapeutic efficacy of Ethyl biscoumacetate can be increased when used in combination with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabexateEthyl biscoumacetate may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinGarenoxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
GatifloxacinGatifloxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
GefitinibGefitinib may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
GemfibrozilGemfibrozil may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
GemifloxacinGemifloxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
GenisteinGenistein may decrease the anticoagulant activities of Ethyl biscoumacetate.Investigational
GestodeneGestodene may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
GestonoroneThe therapeutic efficacy of Ethyl biscoumacetate can be decreased when used in combination with Gestonorone.Experimental
GestrinoneThe therapeutic efficacy of Ethyl biscoumacetate can be decreased when used in combination with Gestrinone.Approved
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Ginkgo biloba is combined with Ethyl biscoumacetate.Approved, Investigational, Nutraceutical
GinsengGinseng may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational, Nutraceutical
GlibornurideGlibornuride may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational, Withdrawn
GliclazideGliclazide may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
GlimepirideGlimepiride may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
GlipizideGlipizide may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
GliquidoneGliquidone may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
GlisoxepideGlisoxepide may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
GLPG-0492GLPG-0492 may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
Glucagon recombinantGlucagon recombinant may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
GlutethimideThe metabolism of Ethyl biscoumacetate can be increased when combined with Glutethimide.Approved, Illicit
GlyburideGlyburide may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
GrepafloxacinGrepafloxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational, Withdrawn
GriseofulvinThe serum concentration of Ethyl biscoumacetate can be decreased when it is combined with Griseofulvin.Approved, Investigational, Vet Approved
GuacetisalGuacetisal may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
HeminHemin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
Hemoglobin crosfumarilHemoglobin crosfumaril may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
HeparinHeparin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
HexestrolHexestrol may decrease the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
HexobarbitalThe metabolism of Ethyl biscoumacetate can be increased when combined with Hexobarbital.Approved
HigenamineHigenamine may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
HydrochlorothiazideThe therapeutic efficacy of Ethyl biscoumacetate can be increased when used in combination with Hydrochlorothiazide.Approved, Vet Approved
Hydroxyprogesterone caproateThe therapeutic efficacy of Ethyl biscoumacetate can be decreased when used in combination with Hydroxyprogesterone caproate.Approved, Investigational
HydroxytyrosolHydroxytyrosol may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Ethyl biscoumacetate is combined with Ibritumomab tiuxetan.Approved, Investigational
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Ethyl biscoumacetate.Approved
IbudilastIbudilast may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
IbuprofenThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Ethyl biscoumacetate.Approved
IbuproxamIbuproxam may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
IcatibantIcatibant may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
IcosapentIcosapent may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Nutraceutical
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational, Nutraceutical
IdraparinuxIdraparinux may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
IfenprodilIfenprodil may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational, Withdrawn
IfetrobanIfetroban may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
IfosfamideIfosfamide may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
IloprostIloprost may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
Imidazole salicylateImidazole salicylate may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
ImipramineImipramine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
IndalpineIndalpine may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational, Withdrawn
IndobufenIndobufen may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
IndomethacinIndomethacin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
IndoprofenIndoprofen may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
IprindoleIprindole may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
IsoxicamIsoxicam may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
ItraconazoleThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Itraconazole.Approved, Investigational
IvermectinIvermectin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational, Vet Approved
JosamycinThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Josamycin.Approved, Investigational
KebuzoneKebuzone may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
KetanserinKetanserin may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
KetoconazoleThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenKetoprofen may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved
KetorolacKetorolac may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
KitasamycinThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Kitasamycin.Experimental
L-CarnitineL-Carnitine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
LansoprazoleThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Lansoprazole.Approved, Investigational
LeflunomideLeflunomide may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
LepirudinEthyl biscoumacetate may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanEthyl biscoumacetate may increase the anticoagulant activities of Letaxaban.Investigational
LevofloxacinLevofloxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Ethyl biscoumacetate.Approved, Investigational
LevonorgestrelLevonorgestrel may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
LevothyroxineLevothyroxine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Ethyl biscoumacetate.Approved, Investigational
LinsidomineLinsidomine may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
LiothyronineLiothyronine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved
LiotrixLiotrix may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
LisofyllineLisofylline may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
LixisenatideLixisenatide can cause a decrease in the absorption of Ethyl biscoumacetate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
LofepramineLofepramine may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
LomefloxacinLomefloxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
LonazolacLonazolac may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
LornoxicamLornoxicam may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
LoxoprofenLoxoprofen may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
LumiracoxibLumiracoxib may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
LynestrenolLynestrenol may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
Magnesium salicylateMagnesium salicylate may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
MasoprocolMasoprocol may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
Meclofenamic acidMeclofenamic acid may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved
MedrogestoneThe therapeutic efficacy of Ethyl biscoumacetate can be decreased when used in combination with Medrogestone.Approved
Medroxyprogesterone acetateMedroxyprogesterone acetate may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
Mefenamic acidMefenamic acid may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
Megestrol acetateThe therapeutic efficacy of Ethyl biscoumacetate can be decreased when used in combination with Megestrol acetate.Approved, Investigational, Vet Approved
MelagatranEthyl biscoumacetate may increase the anticoagulant activities of Melagatran.Experimental
MelitracenMelitracen may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental, Investigational
MeloxicamMeloxicam may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved
MesalazineMesalazine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
MesteroloneMesterolone may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
MestranolMestranol may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved
MetahexamideMetahexamide may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
MetamizoleMetamizole may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational, Withdrawn
MetampicillinMetampicillin may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
MethallenestrilMethallenestril may decrease the anticoagulant activities of Ethyl biscoumacetate.Experimental
MethimazoleMethimazole may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
MethohexitalThe metabolism of Ethyl biscoumacetate can be increased when combined with Methohexital.Approved
Methyl salicylateMethyl salicylate may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved
MethylestrenoloneThe therapeutic efficacy of Ethyl biscoumacetate can be decreased when used in combination with Methylestrenolone.Experimental
MethylphenidateThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe metabolism of Ethyl biscoumacetate can be increased when combined with Methylphenobarbital.Approved
MethyltestosteroneMethyltestosterone may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
MethylthiouracilMethylthiouracil may decrease the anticoagulant activities of Ethyl biscoumacetate.Experimental
MeticillinMeticillin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
MetronidazoleThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Metronidazole.Approved
MezlocillinMezlocillin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
MibefradilThe metabolism of Ethyl biscoumacetate can be decreased when combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Ethyl biscoumacetate.Approved, Investigational
MilrinoneMilrinone may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
MinocyclineMinocycline may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
MizoribineMizoribine may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
MofebutazoneMofebutazone may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
MorniflumateMorniflumate may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
MoxestrolMoxestrol may decrease the anticoagulant activities of Ethyl biscoumacetate.Experimental
MoxifloxacinThe therapeutic efficacy of Ethyl biscoumacetate can be increased when used in combination with Moxifloxacin.Approved, Investigational
Mycophenolate mofetilMycophenolate mofetil may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
Mycophenolic acidMycophenolic acid may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
NabumetoneNabumetone may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
NadroparinEthyl biscoumacetate may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatNafamostat may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
NafcillinNafcillin may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
NaftifineNaftifine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
NaftopidilThe risk or severity of bleeding can be increased when Naftopidil is combined with Ethyl biscoumacetate.Investigational
Nalidixic AcidNalidixic Acid may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
NandroloneNandrolone may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental, Investigational
Nandrolone decanoateNandrolone decanoate may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Illicit
NaproxenNaproxen may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved
NefazodoneNefazodone may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Withdrawn
NemonoxacinNemonoxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
NeomycinNeomycin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved
NepafenacNepafenac may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
NicardipineThe metabolism of Ethyl biscoumacetate can be decreased when combined with Nicardipine.Approved, Investigational
NifenazoneNifenazone may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
Niflumic AcidNiflumic Acid may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
NimesulideThe risk or severity of bleeding and hemorrhage can be increased when Nimesulide is combined with Ethyl biscoumacetate.Approved, Investigational, Withdrawn
NintedanibThe risk or severity of adverse effects can be increased when Ethyl biscoumacetate is combined with Nintedanib.Approved
NitroaspirinNitroaspirin may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
NomegestrolThe therapeutic efficacy of Ethyl biscoumacetate can be decreased when used in combination with Nomegestrol.Approved
Nomegestrol acetateNomegestrol acetate may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
NorelgestrominNorelgestromin may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
NorethisteroneThe therapeutic efficacy of Ethyl biscoumacetate can be decreased when used in combination with Norethisterone.Approved
NorethynodrelNorethynodrel may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved
NorfloxacinNorfloxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
NorgestimateNorgestimate may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
NorgestrelNorgestrel may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved
NorgestrienoneThe therapeutic efficacy of Ethyl biscoumacetate can be decreased when used in combination with Norgestrienone.Experimental
NortriptylineNortriptyline may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
NystatinThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Nystatin.Approved, Vet Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Ethyl biscoumacetate is combined with Obinutuzumab.Approved, Investigational
OfloxacinOfloxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
OleandomycinThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Oleandomycin.Vet Approved
OlopatadineOlopatadine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
OlsalazineOlsalazine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Ethyl biscoumacetate is combined with Omacetaxine mepesuccinate.Approved, Investigational
Omega-3 fatty acidsOmega-3 fatty acids may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Nutraceutical
Omega-3-carboxylic acidsThe therapeutic efficacy of Ethyl biscoumacetate can be increased when used in combination with Omega-3-carboxylic acids.Approved, Investigational
OmeprazoleThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OpipramolOpipramol may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
OrgoteinOrgotein may increase the anticoagulant activities of Ethyl biscoumacetate.Vet Approved
OritavancinThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Oritavancin.Approved, Investigational
OtamixabanOtamixaban may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
OxacillinOxacillin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
OxandroloneOxandrolone may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
OxaprozinOxaprozin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
Oxolinic acidOxolinic acid may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
OxymetholoneOxymetholone may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Illicit
OxyphenbutazoneOxyphenbutazone may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Withdrawn
OxytetracyclineOxytetracycline may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational, Vet Approved
OzagrelOzagrel may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
PalmidrolPalmidrol may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental, Nutraceutical
ParecoxibParecoxib may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
ParnaparinParnaparin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
ParoxetineParoxetine may increase the antiplatelet activities of Ethyl biscoumacetate.Approved, Investigational
ParthenolideParthenolide may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
PazufloxacinPazufloxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
PefloxacinPefloxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
PenamecillinPenamecillin may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
Pentaerythritol TetranitratePentaerythritol Tetranitrate may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
PentobarbitalThe metabolism of Ethyl biscoumacetate can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
Pentosan PolysulfatePentosan Polysulfate may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
PentoxifyllinePentoxifylline may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
PhenindionePhenindione may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
PhenobarbitalThe metabolism of Ethyl biscoumacetate can be increased when combined with Phenobarbital.Approved, Investigational
PhenoxymethylpenicillinPhenoxymethylpenicillin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved
PhenprocoumonPhenprocoumon may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
Phenyl aminosalicylatePhenyl aminosalicylate may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
PhenylbutazonePhenylbutazone may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved
PhenytoinPhenytoin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved
PhylloquinonePhylloquinone may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
PicotamidePicotamide may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
PimecrolimusPimecrolimus may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
Pipemidic acidPipemidic acid may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
PiperacillinPiperacillin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
PirfenidonePirfenidone may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
Piromidic acidPiromidic acid may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
PiroxicamPiroxicam may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
PirprofenPirprofen may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
PivampicillinPivampicillin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
PivmecillinamPivmecillinam may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
Polyestradiol phosphatePolyestradiol phosphate may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved
PomalidomidePomalidomide may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
PosaconazoleThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
Potassium CitrateEthyl biscoumacetate may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
Potassium IodidePotassium Iodide may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved
PranoprofenPranoprofen may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental, Investigational
PrasugrelPrasugrel may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
PrimidoneThe metabolism of Ethyl biscoumacetate can be increased when combined with Primidone.Approved, Vet Approved
Procaine benzylpenicillinProcaine benzylpenicillin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved
ProgesteroneThe therapeutic efficacy of Ethyl biscoumacetate can be decreased when used in combination with Progesterone.Approved, Vet Approved
ProglumetacinProglumetacin may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
PromegestoneThe therapeutic efficacy of Ethyl biscoumacetate can be decreased when used in combination with Promegestone.Experimental
PromestrienePromestriene may decrease the anticoagulant activities of Ethyl biscoumacetate.Investigational
PropacetamolPropacetamol may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
PropafenoneThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Propafenone.Approved
PropicillinPropicillin may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
PropylthiouracilPropylthiouracil may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
PropyphenazonePropyphenazone may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
ProquazoneProquazone may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
Protein CEthyl biscoumacetate may increase the anticoagulant activities of Protein C.Approved
Protein S humanEthyl biscoumacetate may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeEthyl biscoumacetate may increase the anticoagulant activities of Protocatechualdehyde.Approved
ProtriptylineProtriptyline may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
PrulifloxacinPrulifloxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
PTC299PTC299 may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
QuinestrolQuinestrol may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved
QuingestanolQuingestanol may decrease the anticoagulant activities of Ethyl biscoumacetate.Experimental
QuinidineQuinidine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
QuinineQuinine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
RamatrobanRamatroban may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
RelcovaptanRelcovaptan may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
ResveratrolResveratrol may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Experimental, Investigational
ReteplaseReteplase may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
ReviparinEthyl biscoumacetate may increase the anticoagulant activities of Reviparin.Approved, Investigational
RidogrelRidogrel may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
RifabutinThe metabolism of Ethyl biscoumacetate can be increased when combined with Rifabutin.Approved, Investigational
RifampicinThe metabolism of Ethyl biscoumacetate can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Ethyl biscoumacetate can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe metabolism of Ethyl biscoumacetate can be increased when combined with Rifaximin.Approved, Investigational
RivaroxabanEthyl biscoumacetate may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibRofecoxib may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational, Withdrawn
RonifibrateRonifibrate may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
RosoxacinRosoxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
RosuvastatinThe therapeutic efficacy of Ethyl biscoumacetate can be increased when used in combination with Rosuvastatin.Approved
RufloxacinRufloxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
SalicylamideSalicylamide may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
Salicylic acidSalicylic acid may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational, Vet Approved
SalsalateSalsalate may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
SarpogrelateSarpogrelate may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
SaruplaseSaruplase may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
SecobarbitalThe metabolism of Ethyl biscoumacetate can be increased when combined with Secobarbital.Approved, Vet Approved
SecoisolariciresinolSecoisolariciresinol may decrease the anticoagulant activities of Ethyl biscoumacetate.Investigational
SelexipagSelexipag may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
SeliciclibSeliciclib may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
SemapimodSemapimod may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
SeratrodastSeratrodast may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
SerrapeptaseSerrapeptase may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
SertralineSertraline may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
SevofluraneSevoflurane may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved
Silver sulfadiazineThe therapeutic efficacy of Ethyl biscoumacetate can be increased when used in combination with Silver sulfadiazine.Approved, Vet Approved
SimfibrateSimfibrate may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
SitafloxacinSitafloxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental, Investigational
Sodium CitrateEthyl biscoumacetate may increase the anticoagulant activities of Sodium Citrate.Approved, Investigational
SolithromycinThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Solithromycin.Investigational
SparfloxacinSparfloxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
SRT501SRT501 may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
St. John's WortThe metabolism of Ethyl biscoumacetate can be increased when combined with St. John's Wort.Approved, Investigational, Nutraceutical
StanoloneStanolone may increase the anticoagulant activities of Ethyl biscoumacetate.Illicit, Investigational
StanozololStanozolol may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved
StreptokinaseThe risk or severity of hemorrhage can be increased when Streptokinase is combined with Ethyl biscoumacetate.Approved, Investigational
SucralfateSucralfate may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved
SugammadexSugammadex may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
SulbenicillinSulbenicillin may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
SulfadiazineSulfadiazine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational, Vet Approved
SulfamethoxazoleSulfamethoxazole may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
SulfasalazineSulfasalazine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
SulfinpyrazoneThe metabolism of Ethyl biscoumacetate can be decreased when combined with Sulfinpyrazone.Approved
SulfisoxazoleSulfisoxazole may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved
SulindacSulindac may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
SulodexideSulodexide may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
SultamicillinSultamicillin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
SumatriptanThe therapeutic efficacy of Ethyl biscoumacetate can be increased when used in combination with Sumatriptan.Approved, Investigational
SuprofenSuprofen may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Withdrawn
SuxibuzoneSuxibuzone may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
Synthetic Conjugated Estrogens, ASynthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved
Synthetic Conjugated Estrogens, BSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved
TalampicillinTalampicillin may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
TalniflumateTalniflumate may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
TamoxifenTamoxifen may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
TarenflurbilTarenflurbil may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
TegafurThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Tegafur.Approved, Investigational
TelithromycinThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Telithromycin.Approved
TemafloxacinTemafloxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
TenecteplaseTenecteplase may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
TenidapTenidap may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
TenoxicamTenoxicam may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
TepoxalinTepoxalin may increase the anticoagulant activities of Ethyl biscoumacetate.Vet Approved
TeriflunomideTeriflunomide may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
TesmilifeneTesmilifene may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
TestosteroneTestosterone may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
Testosterone cypionateThe therapeutic efficacy of Ethyl biscoumacetate can be increased when used in combination with Testosterone cypionate.Approved
Testosterone enanthateThe therapeutic efficacy of Ethyl biscoumacetate can be increased when used in combination with Testosterone enanthate.Approved
Testosterone propionateTestosterone propionate may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational, Vet Approved, Withdrawn
Testosterone undecanoateThe therapeutic efficacy of Ethyl biscoumacetate can be increased when used in combination with Testosterone undecanoate.Approved, Investigational
TetracyclineTetracycline may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved
ThiamylalThe metabolism of Ethyl biscoumacetate can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Ethyl biscoumacetate can be increased when combined with Thiopental.Approved, Vet Approved
Thyroid, porcineThyroid, porcine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
TianeptineTianeptine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
Tiaprofenic acidTiaprofenic acid may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
TiboloneTibolone may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
TicagrelorTicagrelor may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
TicarcillinTicarcillin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational, Vet Approved
TiclopidineTiclopidine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
TinoridineTinoridine may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
TinzaparinTinzaparin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
TioclomarolTioclomarol may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
TipranavirTipranavir may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
TirofibanTirofiban may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
TolazamideTolazamide may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
TolbutamideTolbutamide may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
Tolfenamic AcidThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Ethyl biscoumacetate.Approved, Investigational
TolmetinTolmetin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
ToremifeneToremifene may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
TositumomabThe risk or severity of adverse effects can be increased when Ethyl biscoumacetate is combined with Tositumomab.Approved, Investigational
TramadolTramadol may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
TranilastThe risk or severity of bleeding can be increased when Tranilast is combined with Ethyl biscoumacetate.Approved, Investigational
TrapidilTrapidil may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
TreprostinilTreprostinil may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
TriamcinoloneTriamcinolone may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved
TribenosideTribenoside may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
TriflusalTriflusal may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
TrimipramineTrimipramine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
TriptolideTriptolide may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
Trolamine salicylateTrolamine salicylate may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
TrovafloxacinTrovafloxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational, Withdrawn
TroxerutinEthyl biscoumacetate may increase the anticoagulant activities of Troxerutin.Investigational
TylosinThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Tylosin.Vet Approved
UlipristalUlipristal may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved
UrokinaseUrokinase may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational, Withdrawn
ValdecoxibValdecoxib may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational, Withdrawn
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Ethyl biscoumacetate.Approved
VerapamilThe metabolism of Ethyl biscoumacetate can be decreased when combined with Verapamil.Approved
Vitamin EVitamin E may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Nutraceutical, Vet Approved
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Ethyl biscoumacetate.Approved
VoriconazoleThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Voriconazole.Approved, Investigational
VorinostatVorinostat may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
WarfarinWarfarin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
XimelagatranXimelagatran may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational, Withdrawn
ZafirlukastThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Zafirlukast.Approved, Investigational
ZaltoprofenZaltoprofen may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
ZeranolZeranol may decrease the anticoagulant activities of Ethyl biscoumacetate.Vet Approved
ZileutonZileuton may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational, Withdrawn
ZimelidineZimelidine may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
ZomepiracZomepirac may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Food Interactions
Not Available

References

Synthesis Reference

Rosicky, J.; U.S. Patent 2,482,511; September 20,1949; assigned to Spojene Farmaceuticke Zovody (Czechoslovakia).

General References
Not Available
External Links
PubChem Compound
54685524
PubChem Substance
99445264
ChemSpider
10444159
BindingDB
35538
ChEBI
135659
ChEMBL
CHEMBL2106261
Wikipedia
Ethyl_biscoumacetate
ATC Codes
B01AA08 — Ethyl biscoumacetate

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)153-154Rosicky, J.; U.S. Patent 2,482,511; September 20,1949; assigned to Spojene Farmaceuticke Zovody (Czechoslovakia).
water solubility153 mg/L (at 20 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
Predicted Properties
PropertyValueSource
Water Solubility0.0677 mg/mLALOGPS
logP2.18ALOGPS
logP1.67ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)4.82ChemAxon
pKa (Strongest Basic)-6.7ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area119.36 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity104.95 m3·mol-1ChemAxon
Polarizability39.98 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.937
Blood Brain Barrier+0.5382
Caco-2 permeable+0.6023
P-glycoprotein substrateSubstrate0.6415
P-glycoprotein inhibitor INon-inhibitor0.7527
P-glycoprotein inhibitor IINon-inhibitor0.7433
Renal organic cation transporterNon-inhibitor0.8741
CYP450 2C9 substrateNon-substrate0.7999
CYP450 2D6 substrateNon-substrate0.9049
CYP450 3A4 substrateNon-substrate0.6717
CYP450 1A2 substrateNon-inhibitor0.6524
CYP450 2C9 inhibitorInhibitor0.8453
CYP450 2D6 inhibitorNon-inhibitor0.9562
CYP450 2C19 inhibitorInhibitor0.6966
CYP450 3A4 inhibitorNon-inhibitor0.9273
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6137
Ames testNon AMES toxic0.6498
CarcinogenicityNon-carcinogens0.9167
BiodegradationNot ready biodegradable0.7564
Rat acute toxicity2.7178 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.938
hERG inhibition (predictor II)Non-inhibitor0.896
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as 4-hydroxycoumarins. These are coumarins that contain one or more hydroxyl groups attached to C4-position the coumarin skeleton.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Coumarins and derivatives
Sub Class
Hydroxycoumarins
Direct Parent
4-hydroxycoumarins
Alternative Parents
1-benzopyrans / Pyranones and derivatives / Benzenoids / Vinylogous acids / Heteroaromatic compounds / Lactones / Carboxylic acid esters / Oxacyclic compounds / Monocarboxylic acids and derivatives / Organic oxides
show 2 more
Substituents
4-hydroxycoumarin / Benzopyran / 1-benzopyran / Pyranone / Pyran / Benzenoid / Heteroaromatic compound / Vinylogous acid / Carboxylic acid ester / Lactone
show 10 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Manganese ion binding
Specific Function
This enzyme has 2 functions: it catalyzes the production of glutamine and 4-aminobutanoate (gamma-aminobutyric acid, GABA), the latter in a pyridoxal phosphate-independent manner (By similarity). E...
Gene Name
GLUL
Uniprot ID
P15104
Uniprot Name
Glutamine synthetase
Molecular Weight
42064.15 Da
References
  1. Sharaev PN, Bogdanov NG, Sarycheva IK, Zhukova EE: [Allosteric regulation of glucosamine synthetase activity by naphthoquinone derivatives and ethyl ester of di-(4-oxycumarinyl-3)-acetic acid]. Biokhimiia. 1981 Feb;46(2):342-6. [PubMed:7195738]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Online Health [Link]

Drug created on October 08, 2010 15:27 / Updated on August 02, 2018 06:10